Cycling to 2nd after 1st line TNFi in AxSpA provides
◦ Limited benefits to pts
◦ Few pts showed clinically meaningful improvement in disease severity after 6 months
◦ Less than 25% pts remained on therapy after 2 years
Mease P Abs1499 https://t.co/0Txs82KRbx #ACR22 @RheumNow https://t.co/xJiIWe9yDp
Links:
The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control…
http://bit.ly/3UXwsTL
13-11-2022
